Market Cap: $1.9B
SI
Sarepta Therapeutics, Inc.
SRPT
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.9B
Sarepta Therapeutics continues to make strides in the biotechnology space with the recent acceptance of supplemental New Drug Applications (sNDAs) for their gene therapies AMONDYS 45 and VYONDYS 53. T…
Sarepta Therapeutics (Ticker: SRPT) is positioning itself for future growth through the development of its small interfering RNA (siRNA) candidates, SRP-1001 and SRP-1003, which are showing promising…
Sarepta Therapeutics Advances Regulatory Strategy Amid Investor Concerns Sarepta Therapeutics is currently focused on submitting supplemental new drug applications to the U.S. Food and Drug Administra…
Sarepta Therapeutics Enters a New Era of Regulatory Dynamics Amidst Leadership Changes at the FDA Sarepta Therapeutics, a leader in gene therapy innovations for genetic diseases, is positioned at a cr…
Regulatory Shifts Signal Opportunities for Biopharmaceutical Innovation Sarepta Therapeutics stands at a potentially transformative juncture in the gene therapy landscape as the U.S. Food and Drug Adm…
Sarepta Therapeutics Navigates Regulatory Challenges Amid FDA Scrutiny In light of recent developments within the biopharmaceutical landscape, Sarepta Therapeutics remains at a pivotal crossroads as r…
Navigating Innovation Amid Regulatory Challenges in Rare Disease Therapies At the recent CNBC Cures Summit in New York City, significant concerns arise about the FDA's role in advancing therapies for…
Congressional Critique Highlights FDA's Challenges in Rare Disease Innovation At the recent CNBC Cures Summit held in New York City, Congressman Jake Auchincloss openly criticizes FDA Commissioner Mar…
Sarepta Therapeutics and the Future of Genetic Medicine Sarepta Therapeutics positions itself as a pioneer in the field of genetic medicine, particularly focusing on innovative treatments for rare dis…
Sarepta Therapeutics Reports Mixed Financial Results Amid Innovative Pipeline Developments Sarepta Therapeutics reveals its latest financial results, indicating a challenging yet dynamic phase for the…
Sarepta Therapeutics Faces Financial Disparity Amid Robust Revenue Growth In a recent financial disclosure, Sarepta Therapeutics grapples with a complex performance narrative that highlights both sign…
Sarepta Therapeutics Advances in Gene Therapy Research Sarepta Therapeutics, a frontrunner in genetic medicine focused on rare diseases, makes significant strides in its gene therapy programs aimed at…
Advancements in Duchenne Muscular Dystrophy Treatment: Dyne Therapeutics' Promising Trial Results Dyne Therapeutics, Inc. has recently unveiled topline results from the Registrational Expansion Cohort…
Dyne Therapeutics Advances Duchenne Muscular Dystrophy Treatment with Promising Trial Results Dyne Therapeutics, Inc. has recently announced the topline results from the Registrational Expansion Cohor…
Innovative Gene Therapy for Duchenne Muscular Dystrophy Gains Momentum Following Recent Tragedies The recent fatalities of two patients with Duchenne muscular dystrophy (DMD) have intensified the focu…
Sarepta Therapeutics Continues to Advance Gene Therapy Pipeline Amid Market Volatility Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, remains focused on its mission to…
Sarepta Therapeutics Advances Genetic Medicine Amid Market Uncertainty Sarepta Therapeutics, a leader in the field of genetic medicine, continues to make significant strides in the development of inno…
Sarepta Therapeutics: Pioneering Advances in Gene Therapy Sarepta Therapeutics, a leader in precision genetic medicine, maintains its commitment to advancing therapies for rare diseases, particularly…
Sarepta Therapeutics Advances Genetic Medicine with FDA Approval for ENDEAVOR Study Sarepta Therapeutics Inc. achieves a significant milestone as the U.S. Food and Drug Administration (FDA) grants app…
Sarepta Therapeutics Advances Genetic Medicine with FDA Approval Sarepta Therapeutics Inc. achieves a significant milestone as the U.S. Food and Drug Administration (FDA) grants approval for dosing in…
Sarepta Therapeutics Advances in Gene Therapy for Rare Diseases Sarepta Therapeutics, a leader in genetic medicine, is currently advancing its innovative gene therapy solutions aimed at treating rare…
### Advancements in Gene Therapy: Sarepta Therapeutics' Pivotal Role in Rare Disease Treatment Sarepta Therapeutics is making significant strides in the field of gene therapy, particularly for rare ge…
Sarepta Therapeutics Advances Gene Therapy for Rare Diseases Sarepta Therapeutics is making significant strides in the development of gene therapies aimed at treating rare genetic disorders, particula…
Sarepta Therapeutics Faces Challenges with Elevidys Amid FDA Warning Sarepta Therapeutics, Inc. is currently navigating a complex landscape following the U.S. Food and Drug Administration's (FDA) rece…
Sarepta Therapeutics: Innovating in Gene Therapy Amidst Industry Developments Sarepta Therapeutics is at the forefront of the biotechnology sector, particularly in the realm of gene therapy. Known for…